company background image
KROS

Keros Therapeutics NasdaqGM:KROS Stock Report

Last Price

US$50.40

Market Cap

US$1.4b

7D

0.6%

1Y

-6.0%

Updated

08 Dec, 2022

Data

Company Financials +
KROS fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

KROS Stock Overview

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need.

Keros Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Keros Therapeutics
Historical stock prices
Current Share PriceUS$50.40
52 Week HighUS$68.29
52 Week LowUS$24.38
Beta1.2
1 Month Change11.88%
3 Month Change29.33%
1 Year Change-6.02%
3 Year Changen/a
5 Year Changen/a
Change since IPO151.00%

Recent News & Updates

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Sep 08
Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Keros Therapeutics GAAP EPS of -$1.13 misses by $0.07

Aug 04

Recent updates

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Sep 08
Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Apr 29
Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

Jan 24
We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

Oct 10
Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth

We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

May 05
We're Hopeful That Keros Therapeutics (NASDAQ:KROS) Will Use Its Cash Wisely

Are Insiders Buying Keros Therapeutics, Inc. (NASDAQ:KROS) Stock?

Mar 13
Are Insiders Buying Keros Therapeutics, Inc. (NASDAQ:KROS) Stock?

We're Not Very Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Rate

Jan 19
We're Not Very Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Rate

Have Insiders Been Buying Keros Therapeutics, Inc. (NASDAQ:KROS) Shares?

Nov 27
Have Insiders Been Buying Keros Therapeutics, Inc. (NASDAQ:KROS) Shares?

Shareholder Returns

KROSUS BiotechsUS Market
7D0.6%-0.3%-3.7%
1Y-6.0%-11.2%-21.2%

Return vs Industry: KROS exceeded the US Biotechs industry which returned -11.2% over the past year.

Return vs Market: KROS exceeded the US Market which returned -21.2% over the past year.

Price Volatility

Is KROS's price volatile compared to industry and market?
KROS volatility
KROS Average Weekly Movement7.7%
Biotechs Industry Average Movement11.1%
Market Average Movement7.4%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market3.3%

Stable Share Price: KROS is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: KROS's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2015104Jas Seehrahttps://www.kerostx.com

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company’s lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension.

Keros Therapeutics, Inc. Fundamentals Summary

How do Keros Therapeutics's earnings and revenue compare to its market cap?
KROS fundamental statistics
Market CapUS$1.39b
Earnings (TTM)-US$81.90m
Revenue (TTM)US$20.00m

69.4x

P/S Ratio

-16.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
KROS income statement (TTM)
RevenueUS$20.00m
Cost of RevenueUS$81.23m
Gross Profit-US$61.23m
Other ExpensesUS$20.67m
Earnings-US$81.90m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.97
Gross Margin-306.16%
Net Profit Margin-409.50%
Debt/Equity Ratio0%

How did KROS perform over the long term?

See historical performance and comparison